Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy) - PRECIOUS Egypt

Study identifier:D134BR00005

ClinicalTrials.gov identifier:NCT07221331

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

Medical condition

Neurofibromatosis Type 1

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 19 Nov 2025
Estimated Primary Completion Date: 30 Sept 2026
Estimated Study Completion Date: 30 Sept 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria